Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis
Background: Recently, many studies have explored the relationship between the expression of programmed death ligand 1 (PD-L1) and prognosis in gastric cancer, but there is still controversy. Additionally, few studies have specifically investigated the expression of PD-L1 in patients with peritoneal...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/7/2003 |
| _version_ | 1797590169469059072 |
|---|---|
| author | Xiao-Jiang Chen Cheng-Zhi Wei Jun Lin Ruo-Peng Zhang Guo-Ming Chen Yuan-Fang Li Run-Cong Nie Yong-Ming Chen |
| author_facet | Xiao-Jiang Chen Cheng-Zhi Wei Jun Lin Ruo-Peng Zhang Guo-Ming Chen Yuan-Fang Li Run-Cong Nie Yong-Ming Chen |
| author_sort | Xiao-Jiang Chen |
| collection | DOAJ |
| description | Background: Recently, many studies have explored the relationship between the expression of programmed death ligand 1 (PD-L1) and prognosis in gastric cancer, but there is still controversy. Additionally, few studies have specifically investigated the expression of PD-L1 in patients with peritoneal metastasis. Methods: Immunohistochemistry was used to analyze the expression of PD-L1 in gastric cancer patients with peritoneal metastasis. The combined positive score (CPS) was calculated to evaluate the expression of PD-L1, and the clinicopathological data were analyzed to explore prognostic significance. Results: In total, 147 gastric cancer patients with peritoneal metastasis were enrolled. The negative PD-L1 expression was defined as a CPS < 1, and high PD-L1 expression was defined as a CPS ≥ 10. PD-L1 expression with CPS ≥ 1 and CPS-negative was detected in 67 (45.58%) and 80 (54.42%) patients, respectively. High PD-L1 expression at PD-L1 CPS ≥ 10 was detected in 21(14.29%) patients. The median overall survival (OS) was 18.53 months in the CPS < 10 group and 27.00 months in the CPS ≥ 10 group; the OS difference between the two groups was significant (<i>p</i> = 0.015). Multivariate analysis demonstrated that a poor Eastern Cooperative Oncology Group performance score (ECOG PS) (<i>p</i> = 0.002) and severe peritoneal metastasis (<i>p</i> = 0.033) were significantly associated with poor survival, while palliative chemotherapy (<i>p</i> = 0.002) and high PD-L1 expression (<i>p</i> = 0.008) were independent and significantly favorable prognostic factors. Conclusions: Our study demonstrated that PD-L1 expression was widely presented in gastric cancer patients with peritoneal metastasis, while a CPS no less than 10 predicted better prognosis. |
| first_indexed | 2024-03-11T01:16:41Z |
| format | Article |
| id | doaj.art-710ac4c5d84b42eb8c704c2b6defdbeb |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-11T01:16:41Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-710ac4c5d84b42eb8c704c2b6defdbeb2023-11-18T18:28:04ZengMDPI AGBiomedicines2227-90592023-07-01117200310.3390/biomedicines11072003Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal MetastasisXiao-Jiang Chen0Cheng-Zhi Wei1Jun Lin2Ruo-Peng Zhang3Guo-Ming Chen4Yuan-Fang Li5Run-Cong Nie6Yong-Ming Chen7State Key Laboratory of Oncology in South China, Department of Gastric Surgery, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No.651 Dongfeng Road East, Guangzhou 510060, ChinaState Key Laboratory of Oncology in South China, Department of Gastric Surgery, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No.651 Dongfeng Road East, Guangzhou 510060, ChinaState Key Laboratory of Oncology in South China, Department of Gastric Surgery, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No.651 Dongfeng Road East, Guangzhou 510060, ChinaState Key Laboratory of Oncology in South China, Department of Gastric Surgery, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No.651 Dongfeng Road East, Guangzhou 510060, ChinaState Key Laboratory of Oncology in South China, Department of Gastric Surgery, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No.651 Dongfeng Road East, Guangzhou 510060, ChinaState Key Laboratory of Oncology in South China, Department of Gastric Surgery, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No.651 Dongfeng Road East, Guangzhou 510060, ChinaState Key Laboratory of Oncology in South China, Department of Gastric Surgery, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No.651 Dongfeng Road East, Guangzhou 510060, ChinaState Key Laboratory of Oncology in South China, Department of Gastric Surgery, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No.651 Dongfeng Road East, Guangzhou 510060, ChinaBackground: Recently, many studies have explored the relationship between the expression of programmed death ligand 1 (PD-L1) and prognosis in gastric cancer, but there is still controversy. Additionally, few studies have specifically investigated the expression of PD-L1 in patients with peritoneal metastasis. Methods: Immunohistochemistry was used to analyze the expression of PD-L1 in gastric cancer patients with peritoneal metastasis. The combined positive score (CPS) was calculated to evaluate the expression of PD-L1, and the clinicopathological data were analyzed to explore prognostic significance. Results: In total, 147 gastric cancer patients with peritoneal metastasis were enrolled. The negative PD-L1 expression was defined as a CPS < 1, and high PD-L1 expression was defined as a CPS ≥ 10. PD-L1 expression with CPS ≥ 1 and CPS-negative was detected in 67 (45.58%) and 80 (54.42%) patients, respectively. High PD-L1 expression at PD-L1 CPS ≥ 10 was detected in 21(14.29%) patients. The median overall survival (OS) was 18.53 months in the CPS < 10 group and 27.00 months in the CPS ≥ 10 group; the OS difference between the two groups was significant (<i>p</i> = 0.015). Multivariate analysis demonstrated that a poor Eastern Cooperative Oncology Group performance score (ECOG PS) (<i>p</i> = 0.002) and severe peritoneal metastasis (<i>p</i> = 0.033) were significantly associated with poor survival, while palliative chemotherapy (<i>p</i> = 0.002) and high PD-L1 expression (<i>p</i> = 0.008) were independent and significantly favorable prognostic factors. Conclusions: Our study demonstrated that PD-L1 expression was widely presented in gastric cancer patients with peritoneal metastasis, while a CPS no less than 10 predicted better prognosis.https://www.mdpi.com/2227-9059/11/7/2003gastric cancerperitoneal metastasisPD-L1prognosis |
| spellingShingle | Xiao-Jiang Chen Cheng-Zhi Wei Jun Lin Ruo-Peng Zhang Guo-Ming Chen Yuan-Fang Li Run-Cong Nie Yong-Ming Chen Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis Biomedicines gastric cancer peritoneal metastasis PD-L1 prognosis |
| title | Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis |
| title_full | Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis |
| title_fullStr | Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis |
| title_full_unstemmed | Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis |
| title_short | Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis |
| title_sort | prognostic significance of pd l1 expression in gastric cancer patients with peritoneal metastasis |
| topic | gastric cancer peritoneal metastasis PD-L1 prognosis |
| url | https://www.mdpi.com/2227-9059/11/7/2003 |
| work_keys_str_mv | AT xiaojiangchen prognosticsignificanceofpdl1expressioningastriccancerpatientswithperitonealmetastasis AT chengzhiwei prognosticsignificanceofpdl1expressioningastriccancerpatientswithperitonealmetastasis AT junlin prognosticsignificanceofpdl1expressioningastriccancerpatientswithperitonealmetastasis AT ruopengzhang prognosticsignificanceofpdl1expressioningastriccancerpatientswithperitonealmetastasis AT guomingchen prognosticsignificanceofpdl1expressioningastriccancerpatientswithperitonealmetastasis AT yuanfangli prognosticsignificanceofpdl1expressioningastriccancerpatientswithperitonealmetastasis AT runcongnie prognosticsignificanceofpdl1expressioningastriccancerpatientswithperitonealmetastasis AT yongmingchen prognosticsignificanceofpdl1expressioningastriccancerpatientswithperitonealmetastasis |